Sera Prognostics (NASDAQ:SERA) and Basel Medical Group (NASDAQ:BMGL) Head to Head Survey

Sera Prognostics (NASDAQ:SERA) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

Sera Prognostics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Basel Medical Group has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.

Profitability

This table compares Sera Prognostics and Basel Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-39,417.29%	-37.50%	-29.02%
Basel Medical Group	N/A	N/A	N/A

Valuation & Earnings

This table compares Sera Prognostics and Basel Medical Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80,000.00	983.39	-$31.93 million	($0.68)	-2.96
Basel Medical Group	$8.90 million	1.28	-$9.50 million	N/A	N/A

Basel Medical Group has higher revenue and earnings than Sera Prognostics.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sera Prognostics and Basel Medical Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1	0	0	1	2.50
Basel Medical Group	1	0	0	0	1.00

Sera Prognostics currently has a consensus target price of $5.00, indicating a potential upside of 148.76%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Basel Medical Group.

Institutional & Insider Ownership

54.6% of Sera Prognostics shares are held by institutional investors. 13.5% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sera Prognostics beats Basel Medical Group on 7 of the 12 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.